| |
SUVmax
|
TLuG
|
ΔLung function
|
|---|
|
Pre
|
Post
|
Δ (%)
|
Pre
|
Post
|
Δ (%)
|
ΔFVC (%)
|
ΔFEV1 (%)
|
ΔDLCoc (%)
|
|---|
|
Pt A
|
11.2
|
14.7
|
+ 32.4
|
6606
|
5826
|
− 11.8
|
− 0.7
|
− 5.1
|
+ 9.8
|
|
Pt C
|
2.1
|
1.6
|
− 23.4
|
1827
|
2178
|
+ 19.2
|
− 4.1
|
− 5.3
|
0.0
|
|
Pt D
|
6.2
|
6.8
|
+ 9.7
|
4616
|
3596
|
− 22.1
|
− 10.7
|
− 8.1
|
− 4.8
|
|
Pt E
|
0.6
|
0.9
|
+ 50
|
2999
|
2555
|
− 16.8
|
− 16.7
|
− 2.2
|
+ 4.1
|
- Δ change before and after infliximab therapy, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, DLCOc diffusing capacity of the lung for carbon monoxide corrected for haemoglobin, SUVmax maximum standardized uptake value, TLuG total lung glycolysis
